The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


The Journal of Immunology, 1974, 112: 792-803.
Copyright © 1974 by The American Association of Immunologists, Inc.

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Resch, K.
Right arrow Articles by Prester, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Resch, K.
Right arrow Articles by Prester, M.

Antibody-Mediated Target Cell Lysis by Nonimmune Cells: The Use of Anti-Immunoglobulin to Distinguish Effector Cell Populations1

Klaus Resch2, Erwin W. Gelfand and Marlot Prester

From the Max-Planck-Institut für Immunbiologie, Freiburg, Germany and the Department of Immunology, Research Institute, The Hospital for Sick Children, Toronto, Canada

Abstract

The role of a goat IgG anti-rabbit immunoglobulin on antibody-mediated target cell lysis by nonimmune cells was investigated. Using a homologous system of rabbit effector cells and rabbit anti-fowl erythrocyte serum, two populations of cells effective in the lysis of antibody-coated target cells could be differentiated by anti-immunoglobulin. In the presence of the anti-immunoglobulin, the cytotoxicity caused by phagocytic cells was suppressed. The IgG or (Fab')2 fraction of the anti-immunoglobulin enhanced target cell destruction initiated by purified lymph node and spleen lymphocytes and to a lesser extent that initiated by purified thymus cells. Monovalent (Fab) anti-immunoglobulin decreased the cytotoxic activity of all effector cells. The mechanism of enhancement appeared to be due to cross-linking between effector lymphocytes and antibody-coated target cells by the divalent anti-immunoglobulin.

Footnotes

1 Supported by grants from the Deutsche Forschungsgemeinschaft and the Medical Research Council of Canada (MA4875).

2 Address all correspondence to: Dr. Klaus Resch, Max-Planck-Institut für Immunbiologie, D-78 Freiburg i. Br., Stübeweg 51, West Germany.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1974 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1974 by The American Association of Immunologists, Inc. All rights reserved.